Page last updated: 2024-12-07

3'-azido-3'-deoxy-5'-o-beta-glucopyranuronosylthymidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine: major metabolite of zidovudine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21591811
CHEBI ID188290
MeSH IDM0157061

Synonyms (18)

Synonym
azt glucuronide
CHEBI:188290
zidovudine glucuronide
(2s,3s,4s,5r,6r)-6-[[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
gazt
unii-cd09f5jm6t
thymidine, 3'-azido-3'-deoxy-5'-o-beta-d-glucopyranuronosyl-
cd09f5jm6t ,
3'-azido-3'-deoxy-5'-o-beta-glucopyranuronosylthymidine
3'-deoxy-3'-azidothymidine-5'-.beta.-glucuronide
thymidine, 3'-azido-3'-deoxy-5'-o-.beta.-d-glucopyranuronosyl-
gzdv
azt 5'-glucuronide
Q27275403
PD039977
CS-0880291
HY-137522A
zidovudine o-|a-d-glucuronide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The major adverse effect of zidovudine (ZDV) is haematological toxicity which results in anaemia and granulocytopenia."( Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.
Back, DJ; Barry, M; Beeching, N; Breckenridge, AM; Howe, JL; Nye, F; Swart, AM; Weller, IV, 1994
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
"A pharmacokinetic evaluation of a potential drug interaction between zidovudine (AZT) and dideoxycytidine (ddC) was conducted in monkeys."( Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
Gallo, JM; Mehta, M; Qian, MX; Swagler, AR; Vishwanathan, CT, 1992
)
0.28
") and 12-h oral pharmacokinetic studies were conducted at weeks 1, 6, and 12."( Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients.
Bonnez, W; Marder, V; Morse, GD; Olson, J; Plank, C; Portmore, AC; Reichman, RC; Taylor, C, 1992
)
0.28
" Data were analysed by noncompartmental methods to obtain pharmacokinetic parameters for each drug."( Pharmacokinetics of anti-HIV nucleosides in microswine.
Gallo, JM; Qian, MX; Swagler, AR, 1991
)
0.28
"The anti-human immunodeficiency virus drug zidovudine is metabolized extensively in human beings to the 5'-glucuronide (GAZT) and is cleared rapidly, resulting in a short half-life and the need for frequent dosing."( Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex.
Blum, MR; Broder, S; de Miranda, P; Good, SS; Myers, CE; Thomas, RV; Yarchoan, R, 1989
)
0.28
"Our objective was to determine whether a pharmacokinetic interaction exists between zidovudine and didanosine when they are coadministered."( Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients.
Cameron, W; Gallicano, K; Garber, G; Pakuts, A; Sahai, J, 1995
)
0.29
"Zidovudine is metabolized to an inactive 5'-glucuronide and has a short plasma half-life requiring frequent dosing."( Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus.
Agrawal, KC; Akula, S; George, WJ; Greenspan, DL; Hyslop, NE; Lertora, JJ; Rege, AB, 1994
)
0.29
"To investigate a possible pharmacokinetic interaction between zidovudine and paracetamol."( Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug.
Beijnen, JH; Burger, DM; Koks, CH; Meenhorst, PL; Underberg, WJ; van der Heijde, JF, 1994
)
0.29
" Pharmacokinetic monitoring was performed on day 0 (AZT alone) and after 7 days of combined use of paracetamol and AZT."( Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug.
Beijnen, JH; Burger, DM; Koks, CH; Meenhorst, PL; Underberg, WJ; van der Heijde, JF, 1994
)
0.29
"Combined use of paracetamol and AZT did not result in a significant change in any of the calculated pharmacokinetic parameters of AZT or its primary metabolite AZT-glucuronide."( Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug.
Beijnen, JH; Burger, DM; Koks, CH; Meenhorst, PL; Underberg, WJ; van der Heijde, JF, 1994
)
0.29
" The aim of this study was to investigate the possibility of a pharmacokinetic drug interaction between ZDV and ddI."( Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
Back, DJ; Barry, M; Beeching, N; Bergin, C; Breckenridge, AM; Howe, JL; Mulcahy, F; Nye, F; Ormesher, S, 1994
)
0.29
" There were no significant differences in the pharmacokinetic parameters between the two groups of patients."( Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.
Back, DJ; Barry, M; Beeching, N; Breckenridge, AM; Howe, JL; Nye, F; Swart, AM; Weller, IV, 1994
)
0.29
"A potential pharmacokinetic interaction between rifampin (Rimactan, Rifadin) and zidovudine (AZT, Retrovir) was investigated in the population of human immunodeficiency virus-infected patients at our hospital."( Pharmacokinetic interaction between rifampin and zidovudine.
Beijnen, JH; Burger, DM; Koks, CH; Meenhorst, PL, 1993
)
0.29
" This study was conducted to determine the pharmacokinetic parameters of ZDV in patients with asymptomatic HIV infection and liver disease."( Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).
Brouwer, KL; Cheeseman, SH; Eyster, E; Lemon, SM; Moore, KH; Opheim, K; Raasch, RH; van der Horst, CM, 1995
)
0.29
" Pharmacokinetic parameters were determined for zidovudine and its glucuronide metabolite and compared with use of analysis of variance (ANOVA) appropriate for a repeated-measures design."( Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.
Cameron, DW; Gallicano, K; Pakuts, A; Sahai, J; Seguin, I; Swick, L, 1995
)
0.29
" In order to determine the microsomal enzyme activity, the 6-beta-hydroxycortisol/17-hydroxycorticosteroid ratio and antipyrine pharmacokinetic parameters were determined."( Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
Barthel, B; Brockmeyer, NH; Goos, M; Mertins, L; Tillmann, I, 1997
)
0.3
" Statistical analysis of trough plasma level data indicated that steady-state levels of zidovudine and its glucuronide in plasma had been attained when pharmacokinetic assessments were made on days 4 and 17."( Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.
Pei, JC; Pike, IM; Van Harken, DR; Wagner, J, 1997
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
" Because zidovudine is frequently combined with other drugs, complete knowledge of interactions is essential to optimize AIDS therapy."( 3'-azido-3'-deoxythymidine drug interactions. Screening for inhibitors in human liver microsomes.
Catalin, J; Lacarelle, B; Placidi, M; Rahmani, R; Rajaonarison, JF,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Each of six animals received 20 mg/kg of AZT intragastrically in the absence and presence of an intravenous steady-state dosage regimen of ddC."( Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
Gallo, JM; Mehta, M; Qian, MX; Swagler, AR; Vishwanathan, CT, 1992
)
0.28
" To avoid important cumulation of zidovudine after repeated dosing in patients with acquired immunodeficiency syndrome who have hepatic impairment, a dosage adjustment could be proposed."( Pharmacokinetics of zidovudine in patients with liver cirrhosis.
Chaput, JC; Colin, JN; Delfraissy, JF; Naveau, S; Singlas, E; Taburet, AM; Zorza, G, 1990
)
0.28
" The results presented here are the maternal pharmacokinetics from a series of experiments to delineate more clearly the complex maternal-fetal pharmacokinetics and the effects of AZT in the chronically instrumented maternal and fetal baboon during both steady state intravenous infusion and oral bolus dosage regimens."( Zidovudine kinetics in the pregnant baboon.
Daniel, SS; Garland, M; Myers, MM; Stark, RI; Szeto, HH; Tropper, PJ, 1996
)
0.29
" Patients with mild hepatic disease may require dosage adjustment to avoid accumulation of ZDV after extended therapy."( Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).
Brouwer, KL; Cheeseman, SH; Eyster, E; Lemon, SM; Moore, KH; Opheim, K; Raasch, RH; van der Horst, CM, 1995
)
0.29
" Based on the observation that neither cimetidine nor ranitidine had a significant effect on serum concentrations of zidovudine or zidovudine glucuronide, a change in the dosage of zidovudine is not warranted."( The effect of cimetidine and ranitidine administration with zidovudine.
Balfour, HH; Fletcher, CV; Henry, WK; Noormohamed, SE; Rhame, FS,
)
0.13
" The enterohepatic metabolism of AZT, the effect of such a dosing schedule and the effects of circulating levels of GAZT on outcomes in HIV-infected patients with ESRD must be further investigated."( Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease.
Gordon, AM; Kimmel, PL; Lew, SQ; Li, PP; Straw, J; Umana, WO,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidine 2',3'-dideoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (6.00)18.7374
1990's42 (84.00)18.2507
2000's3 (6.00)29.6817
2010's1 (2.00)24.3611
2020's1 (2.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (17.86%)5.53%
Reviews2 (3.57%)6.00%
Case Studies2 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other42 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]